Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Reference20 articles.
1. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have a higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62–65.
2. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662–669.
3. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105:978–980.
4. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1463.
5. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ucm293101.htm . Posted Feb 28, 2012. Accessed May 1, 2014.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献